Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review [PDF]
Clinical Parkinsonism & Related Disorders, 2022 Dopamine agonist withdrawal syndrome (DAWS) has been introduced to describe the constellation of symptoms resulting from reduction or suspension of dopamine agonist medications.
Xiomara Garcia +4 more
doaj +2 more sources
Predictors of dopamine agonist resistance in prolactinoma patients [PDF]
BMC Endocrine Disorders, 2020 Background Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we
Elle Vermeulen +6 more
doaj +2 more sources
Irreversible extreme freezing of gait after dopamine agonist withdrawal [PDF]
Clinical Case Reports, 2021 Dopamine agonist withdrawal can cause freezing of gait in PD patients.
Mehri Salari +4 more
doaj +2 more sources
Dopamine agonist monotherapy utilization in patients with Parkinson’s disease [PDF]
Clinical Parkinsonism & Related Disorders, 2023 Objectives: To characterize patients with Parkinson’s disease (PD) who initiated dopamine agonist (DA) monotherapy, describe medication utilization and provider types, and estimate medication adherence and discontinuation rates.
Monica Frazer +3 more
doaj +2 more sources
Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors
Parkinson's Disease, 2021 Objective. To investigate the use of dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors in the Norwegian population, between 1 July 2006 and 31 December 2016.
Caroline D. Binde +2 more
doaj +1 more source
Dopamine inhibits mitochondrial motility in hippocampal neurons. [PDF]
PLoS ONE, 2008 The trafficking of mitochondria within neurons is a highly regulated process. In an earlier study, we found that serotonin (5-HT), acting through the 5-HT1A receptor subtype, promotes axonal transport of mitochondria in cultured hippocampal neurons by ...
Sigeng Chen +2 more
doaj +1 more source
Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA. [PDF]
PLoS ONE, 2012 Dopamine D(2) receptor partial agonist antipsychotic drugs can modulate dopaminergic neurotransmission as functional agonists or functional antagonists.
Hiroshi Ito +8 more
doaj +1 more source
Probing the role of the cation–π interaction in the binding sites of GPCRs using unnatural amino acids [PDF]
, 2009 We describe a general application of the nonsense suppression methodology for unnatural amino acid incorporation to probe drug–receptor interactions in functional G protein-coupled receptors (GPCRs), evaluating the binding sites of both the M2 muscarinic
Ballesteros +31 more
core +3 more sources
An approach for identifying brainstem dopaminergic pathways using resting state functional MRI. [PDF]
, 2014 Here, we present an approach for identifying brainstem dopaminergic pathways using resting state functional MRI. In a group of healthy individuals, we searched for significant functional connectivity between dopamine-rich midbrain areas (substantia nigra;
D'Esposito, Mark +3 more
core +8 more sources
Journal of Medical Case Reports, 2019 Background Dopamine agonists are the standard first-line medical therapy for prolactinoma. We report a rare case of giant prolactinoma with a first epileptic seizure due to rapid reduction of the tumor as a complication of dopamine agonist therapy.
Motofumi Koguchi +6 more
doaj +1 more source